THE APEX TIMES
The deal, reported to be potentially worth $2.6 billion, shifts Pfizer toward next-generation cell therapy where engineered immune cells are programmed inside the body rather than manufactured outside.
Pfizer is moving into the next wave of cell therapies with a new collaboration in China focused on “in vivo” CAR-T, a strategy designed to reprogram a patient’s immune cells inside the body. The approach contrasts with traditional CAR-T manufacturing, where engineered cells are built outside the body before being infused back to treat disease.
According to the report, the collaboration could be worth as much as $2.6 billion, underscoring the financial scale companies are willing to commit as the field pushes toward therapies that may be faster to administer and easier to scale than conventional autologous CAR-T manufacturing.
The target area is autoimmune disease, a therapeutic class that has been challenging for cell therapy developers because immune systems must be altered without causing broad immune suppression. The reported goal is to use engineered cell biology to recalibrate immune activity in a more precise way, even as the company navigates questions that still surround safety and durability for “in vivo” designs.
The report frames Pfizer’s entry as part of a competitive race. Several biotechnology firms are working on in vivo CAR-T platforms, aiming to engineer T cells directly after administration. For Pfizer, the pivot adds to its broader push in immunology and oncology-adjacent platform building, even though the company’s disclosed timeline, endpoints, and clinical stage for this specific program are not detailed in the report.
For the Chinese market, collaborations like this can also matter for regulatory strategy and development execution. Local partners can provide access to clinical networks and translational capabilities, while global companies bring platform know-how and manufacturing development. In this case, the reported deal indicates that Pfizer wants a foothold in a modality that is still moving from early research into larger clinical tests.
What remains unclear from the publicly reported information is the exact therapeutic target, the company or platform behind the “in vivo” approach, and the development plan. The report does not provide details on trial phases, target patient populations, manufacturing or delivery mechanics, or which immuno-oncology or immunology endpoints the parties intend to pursue first.
Investors and industry watchers will likely monitor whether Pfizer’s entry translates into clinical data, since in vivo CAR-T platforms carry unresolved issues such as control of dosing, the risk profile of engineering cells in situ, and the durability of the immune response over time. The reported “potentially $2.6 billion” figure also suggests the agreement includes milestone or option components, but the structure of those payments is not specified in the report.
Next for Pfizer is clarification on the program’s scientific design and regulatory path in China, along with any timetable for moving into human trials and publishing early efficacy and safety results. The company’s communications around partner responsibilities, data sharing, and next-step indications will determine how quickly the market can judge whether this collaboration becomes a cornerstone program or an option-based bet.
Investors moved quickly after early outlines connected United Launch Alliance’s work to the BE-4 engine family, which Blue Origin’s New Glenn is expected to use for a planned 2027 flight carrying AST SpaceMobile’s BlueBird satellites.
A report tied to Anthropic’s debut highlights a cash position large enough to dwarf the combined figures of Amazon and NVIDIA, while also pointing to a new exchange-traded fund built around companies described as “ANT-linked.”
A Yahoo Finance report highlights how Berkshire Hathaway’s roughly $10 billion investment in Alphabet appears to be losing value, with Bill Ackman commenting that the timing and pricing were unexpected even as he noted the stake was bought at a perceived discount.
The company said it has reshaped leadership around national security and export-control oversight after Huang’s exit, emphasizing governance changes ahead of its next quarter and the continuing geopolitical scrutiny on advanced chips.
Anthropic priced its IPO at $83 per share ahead of its debut, while Nvidia heads toward a seventh straight weekly decline amid fresh US pressure on AI chip exports.
A single software issue highlighted weaknesses in payment-related systems, according to a report that described delays affecting Zelle transactions.
The crypto exchange is tied to a move to issue tokenized US stocks on the Base network, raising questions about how onchain share representations could expand access to traditional equities through 24/7 rails.
Goldman Sachs (NYSE:GS) is leading a $280 million round for Payhawk, aiming to expand the startup’s global Finance Operating System that connects payments and spend controls, according to a report citing the deal.
A report citing Cathie Wood’s ARK funds says they sold about $84.8 million of Nvidia shares before the company’s earnings period and used the cash to buy holdings tied to crypto markets.
The change reflects what Berkshire’s latest disclosure says happened to one of its long-running holdings after the company indicated an exit earlier in the year.
Comments
Community guidelines. Comments may be removed for violations.
Loading comments...